Sentences with phrase «works as a tumor»

BRCA1 and 2, genes whose proteins are supposed to work as tumor suppressors and also repair DNA damage, were the first known risk factor genes for familial breast cancer as well as ovarian and other cancers.

«These results showed us that epithelial TRPV1 normally works as a tumor suppressor in the intestines,» said de Jong.

In a series of in vitro experiments, the researchers demonstrated that C / EBPα indeed works as a tumor suppressant by restraining the expression of another molecule known to play a role in triggering and maintaining tumor growth.

Not exact matches

The Kamens claim the main thing that distinguishes their foundation from other brain tumor foundations is their focus on pediatric brain cancer specifically, as well as their close ties with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.

His work indicates that this cell surface marker could serve as a target for a novel brain cancer vaccine or T - cell therapies engineered to recognize and kill tumors carrying that neoantigen.

As researchers learn more about genetic profile of various cancers, other work is charging ahead to deliver personalized vaccines targeted to a patient's own tumor cells

For some years now, a new class of drugs called antibody - drug conjugates (ADCs) have been used, which work in two ways: they consist of an antibody that binds selectively to the tumor cell receptor and interrupts the signal to propagate; they also act as a transport vehicle for a chemical substance that enters the cancer cells with the antibody and triggers their death.

«Our work strongly supports that cancer stem cells are the main source of growth in these tumors and, as such, should be considered promising targets for treatment,» says Mario Suvà, MD, PhD, of the MGH Department of Pathology, co-senior author of the Nature paper.

A glioblastoma tumor requires large amounts of energy as it grows, and the dietary intervention works by drastically limiting the tumor's supply of glucose, Reynolds said.

Chemotherapy aimed at killing single cells may not work as efficiently against bands of spreading tumor cells, she said.

But as noted in a recent Science news story, targeted therapies don't work as well on solid tumors, which usually develop resistance and start growing again.

The class of medications that he conceived, known as immune checkpoint inhibitors, works counterintuitively: By turning off one of the immune system's built - in safeguards, the inhibitors allow T cells — the system's foot soldiers — to attack tumors more effectively.

This cytokine they thought was a treatment for cancer was actually working as an endogenous tumor promoter.

The work also reinforces the importance of finding tumor cell clusters in the blood as a mechanism of detecting cancer metastasis earlier.

They work particularly well if the cancer cells they attack already have defects in the corresponding DNA repair pathways, as it frequently occurs in breast cancer and other tumors.

Early - stage data suggests the investigative LAMP - Vax technology works by fusing tumor antigens to a cellular protein known as LAMP (Lysosomal - Associated Membrane Protein).

«But the immune system can get overwhelmed when there is too much tumor, and not work as effectively as possible,» he says.

Sanford Research scientists are published in Nature Cell Biology for their work developing a model to explore therapies for a pediatric brain tumor known as choroid plexus carcinoma.

Looking forward, Gimi's work will focus on using these microencapsulated cells to stimulate the immune system to act against tumors, as well as activating drug synthesis.

This causes genomic instability in developing immune cells and, in the absence of a working tumor suppressor protein such as p53, an aggressive form of lymphoma develops in mice.

The scientist explains that the nanoparticle works as a bridge of antitumor activation between tumor cells and T lymphocytes.

This work shows that the tumor microenvironment itself can compromise the efficacy of targeted therapies and should be taken into account as new treatment approaches are developed.»

In their previous work, the scientists suspected that C / EBPα may act as a tumor suppressant in normal cells, but the mechanism by which its absence promoted lung cancer tumors remained unclear.

IP5 worked as well as cisplatin in reducing the volumes of the tumors, the team reports today in Cancer Research.

As Fiebig found in his early work, tumor samples do not always successfully graft onto the mice.

Although there is new data coming from Dr. Michel Sadelain's lab and others where they have made a molecule that may work as a CAR T cell that would then bind to NY - ESO - 1 peptides displayed on the surface of a tumor cell.

«Our work supports the idea of exploring the use of Onyx - 015 in tumors that we presumed would be immune to the drug because they were thought to frequently have p53 genes, such as such as melanoma and glioblastoma [a form of brain cancer].

Drugs used in chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

To develop new drugs and determine what treatments are most appropriate for different tumor stages, scientists need to work out what changes occur at a molecular and genetic level as a tumor progresses.

Since starting her new role as an investigator in the In Vivo Pharmacology group at Novartis Oncology, Bhang has been working on using the ClonTracer library to monitor clonal dynamics following drug treatment in cell line and primary tumor xenograft models.

As an active researcher, much of her work is focused on regulation of angiogenesis in pediatric solid tumors, including Wilms» tumor, neuroblastoma, and hepatoblastoma.

DCEG investigators are also working to identify novel molecular and genomic signatures in tumors that are linked to germline genetic variants and environmental exposures, such as cigarette smoking and ionizing radiation.

Their work encompasses several strategies, including: developing FL - HCC animal models to characterize tumor - immune interactions, exploring if a mutated protein associated with FL - HCC could be targeted by immunotherapy, identifying immune checkpoints that could potentially serve as targets for immunotherapy as well as biomarkers for analyzing patients, and evaluating the effectiveness of immunotherapy strategies against FL - HCC patient samples in the lab.

The lab also found that apoptotic tumor cells serve as potent instigators of the T cell immune response and has worked on developing cancer vaccines to mimic PND tumor immunity.

It's called molecular - targeted therapy and it works as advertised: The drugs do disable the molecules that drive growth — but, again, tumors figure out a new way to grow.

As part of our Melanoma Moon Shot, our team of clinicians and scientists work together to study blood and tumors that are collected from patients on these trials.

During his 11 years of extensive work experience in the fields of cell and cancer biology (including work on the famous tumor suppressor gene BRCA1), and biochemistry he has successfully published in peer - reviewed journals such as Molecular and Cell Biology and Cancer Research.

Dual Approach Better for Liver Cancer A combined treatment for liver cancer that uses one oral drug and another delivered directly to tumors in a method known as chemoembolization appears to work better against liver cancer.

Data generated by the working group, which includes molecular profiling of over 10,000 tumors across 33 tumor types as well as a series of results on immune - tumor interaction and response mechanisms, will provide rich characterizations of the relationship between tumors and the immune microenvironment and its impact on patient outcomes.

In combination with this approach, inhibitors of DNA methylation and / or histone deacetylases are expected to relieve repression of DAPK tumor suppressors, whose epigenetic silencing has emerged as a recurring theme from our work and throughout the literature.

A unique focus of my work is on the impact of heterogeneity within tumors and tumor cell populations, including subpopulations commonly referred to as «cancer stem cells», on the immune response.

Recently, Swanton gave a talk at his older daughter's school on his recent work that uncovered HLA loss as a way tumors avoid being recognized by the immune system.

Working with James Hicks, a biologist at USC, the team was able to detect tumor DNA in tiny fragments that had likely been loosed as tumor cells died and broke up.

I had a hunch based on this work that microRNA expression would be different in breast cancer stem cells than in more differentiated tumor cells or normal tissue and that it would change as the stem cells differentiated to form a tumor.

Researchers led by St. Jude Children's Research Hospital scientists have worked out how a crucial cancer - related protein, a «histone writer» called Ezh2, plays a role in suppressing as well as driving the most aggressive form of the brain tumor medulloblastoma.

Building on each other's work, the five award recipients demonstrated how this normal self - defense mechanism can be hijacked by tumors as a way to evade immune surveillance and dodge an attack.

Prior to working at City of Hope, she worked as a research associate in Dr. Peter Lee's lab at Stanford University since 2006 and facilitated in investigating mechanisms causing immune dysfunction in melanoma and breast cancer patients» peripheral blood, lymph node and tumor specimens utilizing techniques including microarray analysis, RT - PCR, Phospho - flow cytometry, histoloogy, and functional FACS studies.

While the drug blocks the effect of estrogen in breast tissue or tumors, it can help estrogen do beneficial work in other parts of the body, such as the heart and bones.

According to Lewis Cantley, director of the Cancer Center at Beth Israel Deaconess Medical Center at Harvard Medical School, as much as 80 percent of all cancers are «driven by either mutations or environmental factors that work to enhance or mimic the effect of insulin on the incipient tumor cells,» Gary Taubes reports, vii adding:

Some of these treatments such as Gerson Therapy work to strengthen and balance the immune system and take some time to be effective while other treatments, such as High Dose Vitamin C intravenous therapy, target cancer cells safely and work right away to decrease tumor load, allowing time for the nutritional program to work.